Ind-Swift Laboratories receives EIR from USFDA for API facility in Punjab

12 May 2020 Evaluate

Ind-Swift Laboratories has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA), for the Surveillance GMP inspection of its API manufacturing facility located at Derabassi, Punjab. The USFDA inspection was conducted from March 9, 2020 to March 13, 2020. The EIR has been issued without any Form 483 observations.

This is the sixth successful USFDA inspection completed by the company. The company supplies 15 APIs to its customers based in U.S. The APIs manufactured from the Derabassi Manufacturing facility are supplied across the World to over 70 countries covering more than 280 customers including all the major drug manufacturers across the Globe.

Ind-Swift Laboratories is engaged in the manufacture of Active Pharmaceutical Ingredients (API). The product range of the company includes Macrolide antibiotics, Cardiovascular, Anti histamine, Anti diabetic, Analgesic, Aromatase inhibtors, Anti depressant,Alcohol absistence, etc.

Ind-Swift Lab. Share Price

129.90 2.25 (1.76%)
28-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1522.40
Dr. Reddys Lab 6405.75
Cipla 1482.00
Zydus Lifesciences 1074.35
Lupin 1625.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.